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Herein we assess the safety of an inhaled formulation of beclomethasone dipropionate (BDP) which uses 
the propellant hydrofluoroalkane-134a (HFA) for the treatment of asthma. Acute local tolerability (as 
assessed by the incidence of cough and mean forced expiratory volume after 1 s inhalation) was similar for 
both BDP and placebo formulated in either chlorofluorocarbon (CFC) or HFA propellants. A total of 43 
patients were treated with HFA-BDP (0,200,400 or 800 pg day-i) or CFC-BDP (800 ug day-i) for 14 days 
and their 24 h urinary free cortisol (UFC) excretion and response to cosyntropin stimulation were 
measured. There was no difference .in UFC between any of the doses of HFA-BDP and CFC-BDP. 
Adrenal responsiveness to cosyntropin stimulation was normal in all but one patient. Two large 12 week 
phase III trials compared HFA-placebo, HFA-BDP 400 lrg day-i and CFC-BDP 800 pg day-i (n = 347), 
and HFA-BDP 800 ,ug day-l and CFC-BDP 1500 ug day-i (n = 233). For HFA-BDP at either dose, 
CFC-BDP 800 p.g day-1 and HFA-placebo, the number of patients with morning plasma cortisol con- 
centrations below normal was less than 4.4% but was 14.6% for CFC-BDP 1500 lrg day-i. The incidence 
of adverse events was lower in the HFA-BDP groups than in the CFC-BDP groups (P = 0.012). The data 
indicate that, at doses of up to 800 ug day-i, HFA-BDP is at least as well tolerated as CFC-BDP. Other 
studies have found that equivalent efficacy is reached at lower doses of HFA-BDP than CFC-BDP. 
Equivalent efficacy at a lower dose and equivalent safety at the same dose imply that HFA-BDP may have 
a more favourable risk: benefit ratio than CFC-BDP when used at the recommended lower doses. 
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Introduction 
Inhaled corticosteroids are widely used as first-line 
preventative therapy in asthma (1) and are recom- 
mended as such in the Global Initiative for Asthma 
treatment guidelines (2), in the British Thoracic 
Society guidelines (3) and by the National Asthma 
Campaign in Australia (4). Various drugs are avail- 
able, but beclomethasone dipropionate (BDP), which 
was among the first to be introduced, is still the most 
widely prescribed. It has been extensively used for the 
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treatment of asthma for many years, and its safety 
profile within the recommended dose range is well 
established (5). The most common delivery device for 
administration of inhaled therapy is the metered dose 
inhaler (MDI), which uses a propellant to create a fine 
aerosol of suspended drug particles (6). Most MD1 
devices use chlorofluorocarbons (CFCs) as the propel- 
lant (6). However, CFCs are known to deplete stratos- 
pheric ozone (6), and the Montreal Protocol of 1987 
has agreed to phase out their use (7). 
Hydrofluoroalkane-134a (HFA) has been developed 
as a suitable alternative propellant. It contains no 
chlorine and therefore has no ozone-depleting poten- 
tial, and it also has a significantly shorter life in 
the atmosphere than CFCs (8). It has been used to 
reformulate a number of inhaled asthma therapies; 
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however, this article concentrates on HFA-BDP 
extrafine aerosol (QvarTM, 3M Pharmaceuticals, St. 
Paul, MN, U.S.A.). 
The safety of HFA, both as the propellant alone 
and in combination with various inhaled medications, 
has been extensively evaluated. HFA has been shown 
to be safe in animal toxicology studies (9, lo), in toler- 
ance studies in healthy volunteers (11, 12) and in 
clinical trials in asthmatic patients (13). It has been 
approved for use in inhalers in more than 40 countries. 
Therefore, HFA, when used with BDP, itself is unlikely 
to generate any new safety issues. 
However, lung deposition studies have found that 
the new formulation of BDP delivers more of the 
given drug to the airways and less to the throat (14). 
As a result, studies needed to be performed on the 
HFA-BDP formulation to establish whether this 
altered delivery pattern could affect the frequency of 
the characteristic side-effects of inhaled cortico- 
steroids. This report focuses on assessment of the 
hypothalamus-pituitary-adrenal (HPA) axis (5, 15), 
the acute topical safety of HFA-BDP (undertaken to 
assess any upper airway irritation) and the adverse 
events observed during the HFA-BDP clinical trial 
programme. 
A reduction in the proportion of BDP impacting on 
the back of the throat should result in a lower inci- 
dence of local side-effects. An increase in the propor- 
tion delivered to the airways will increase the amount 
of drug delivered to the site of therapeutic action but 
may also result in increased systemic bioavailability 
and therefore, possibly, in an increased incidence of 
systemic side-effects. 
Safety Parameters Measured 
Adrenal function, which is an important indicator of 
systemic glucocorticoid effects (15), was assessed in two 
distinct types of studies. One of the more sensitive mea- 
sures of adrenal function is 24 h urinary free cortisol 
(UFC) excretion (15). This, together with a stimulation 
test using an adrenocorticotrophic hormone (ACTH) 
analogue, was employed in a clinical pharmacology 
study. Here, the relatively small number of patients 
enabled verification of all doses and sample collection 
as they spent the entire study period within the clinic. 
In contrast, in the large clinical trials, use of such 
detailed measurements was impractical; the simpler but 
less sensitive measure of morning plasma cortisol con- 
centration was therefore employed. Data from these 
two complementary types of studies are presented 
together in this paper, thus providing a detailed picture 
of the effects of HFA-BDP on adrenal function. 
Acute tolerance was assessed in a cross-over study 
comparing the incidence of cough and mean forced 
expiratory volume after 1 s (FEV,) after inhalation of 
CFC-BDP, CFC-placebo, HFA-BDP and HFA- 
placebo. Full details have been presented elsewhere 
(15). 
Adverse events recorded in several large clinical 
studies are also presented in this paper. 
Results 
ACUTE TOPICAL SAFETY 
A single-dose cross-over study in 18 patients compared 
the effects of high-dose HFA-BDP (200 pg), HFA- 
placebo, CFCBDP (250 ug) and CFC-placebo on 
FEV,. This study has been published in full elsewhere 
(16) but a detailed analysis of safety has not been pre- 
sented. All the patients selected for this study were 
receiving maintenance treatment with budesonide 
administered from a breath-dependent dry-powder 
inhaler. This patient population was selected because 
patients routinely taking inhaled BDP may have 
already developed tolerance to any possible acute 
effects of BDP and may therefore not provide a fair 
assessment of the effect of the CFC formulation or the 
new HFA formulation. 
Each patient received eight inhalations of the rele- 
vant medications on each of the four study days, rep- 
resenting twice the dose of propellant and drug likely 
to be taken at one time in routine practice. Cough 
counts were measured during and immediately follow- 
ing dosing, and FEV, was measured at 2, 10, 20, 40 
and 60 min after dosing. 
As shown in Fig. 1, there were no significant differ- 
ences in the percentage change of FEV, from baseline 
between any of the groups at any time point. Cough 
counts also showed no statistically significant differ- 
ences, although’s trend towards higher cough counts 
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FIG. 1. Effects of HFA-BDP (O), HFA-placebo (m), 
CFC-BDP (0) and CFC-placebo (0) on FEV, in 
asthmatic patients previously taking dry powder 
budesonide inhalers. 
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was seen in the CFC groups. Thus, the acute topical 
effects of HFA propellant and HFA-BDP were at 
least as well tolerated as those of CFC propellant and 
CFC-BDP 
ADRENAL FUNCTION 
The effects of HFA-BDP, CFC-BDP and HFA- 
placebo on adrenal function were investigated in a 
controlled clinical pharmacology study. The study 
population consisted of 43 patients, aged 18-65 years, 
with a clinical diagnosis of asthma of at least 3 
months duration and who had not received corticos- 
teroid therapy for at least 3 months before the study. 
All patients had an FEV, of at least 60% of predicted 
normal value and normal adrenal function before 
study entry. The patients were randomized into five 
parallel groups (HFA-placebo, HFA-BDP 200,400 or 
800 pg day-l or CFC-BDP 800 ug day-l) and received 
study medication for 14 days. Patients were aware of 
whether they were receiving CFC-based or HFA- 
based products, but both patients and physicians were 
blind to the dose of BDP received in the HFA-based 
inhalers. All patients stayed in the study clinic 
throughout the treatment period, ensuring optimal 
inhaler technique, 100% compliance with all medica- 
tion doses and complete collection of samples. UFC 
and response to ACTH stimulation were used to 
assess adrenal function. 
24 h l&nary Free Cortisol Excretion 
Figure 2 presents the percentage change from baseline 
in 24 h UFC excretion after 14 days of treatment. 
There was a dose-dependent fall in 24 h UFC excre- 
tion with increasing doses of HFA-BDP The mean 
percentage change in UFC excretion in patients 
receiving HFA-BDP at a dose of 200 ug day-1 did not 
significantly differ from that in the HFA-placebo 
group, whereas the mean percentage changes in 
UFC excretion in the groups receiving HFA-BDP 400 
ug day-l and 800 pg day-l were significantly lower 
than in the placebo group. There was no statistically 
significant difference between the group receiving 
CFC-BDP 800 ug day-l and the group receiving 
HFA-BDP 800 ug day-l, although the median per- 
centage excretion of 24 h UFC was slightly lower in 
the CFC-BDP group. Thus, at a dose of 800 ug day-l, 
HFA-BDP caused no more adrenal suppression (as 
measured by 24 h UFC) than an equivalent dose of 
CFC-BDP (95% confidence interval -2.16, 47.89 for 
HFA-BDP 800 ug day-l, CFC-BDP 800 I-18 day-l). 
This highly sensitive assay is capable of detecting 
small changes in adrenal function, and it is important 
to retain a perspective on the clinical significance of 
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FIG. 2. Box-and-whisker plot showing effect of 
HFA-BDP (200, 400 or 800 ug day-l), HFA-placebo 
or CFC-BDP (800 pg day-l) on 24 h UFC excretion. 
The central line in each box represents the median 
value for that group, and the upper and lower lines 
represent the 75th and 25th percentiles, respectively. 
The whiskers represent the minimum and maximum 
values obtained, except in the case of outlying values 
(data points which would make the whisker more than 
1.5 times the length of the box), which are shown as 
separate circles. 
the suppression observed. The 800 ug day-l dose of 
CFC-BDP used as the comparator is generally 
accepted as having non-significant clinical effects in 
adult patients (15). 
Response to Adrenocorticotrophic Hormone 
Stimulation 
The response to ACTH stimulation was tested in all 
patients at study entry and after the 14 day treatment 
period. Plasma cortisol was measured before, and at 
30 and 60 min after, injection of cosyntropin (a syn- 
thetic analogue of ACTH). A normal response was 
defined as meeting two of the following three criteria: 
0 normal pre-injection plasma cortisol 
(2 138 nmol 1-t); 
0 normal incremental increase in plasma cortisol 
after injection (2 193.2 nmol 1-l); 
l normal peak plasma cortisol after injection 
(2 496.8 nmol 1-l). 
Only one patient showed an abnormal response on 
two of the three parameters and therefore met the 
study criteria for an abnormal cosyntropin response. 
This single exception was a patient who commenced 
the study with a plasma cortisol level at the low end of 
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the normal range and, after treatment (with HFA- 
BDP 800 ug day-l), showed a low baseline plasma cor- 
tisol level and a low peak value. However, her incre- 
mental response to cosyntropin was normal (2 193.2 
nmol ill), indicating that adrenal responsiveness had 
not been lost. 
PLASMA CORTISOL 
Two large phase III studies included measures of 
morning plasma cortisol concentrations. Patients 
underwent a run-in period of lo-12 days before the 
study, to demonstrate a morning peak expiratory flow 
value of 50&85% of the predicted normal value. All 
patients then received a short course (7-13 days) of 
oral steroid treatment (equivalent to 30 mg day-t of 
prednisolone) and were then randomized to study 
treatment for 12 weeks. In one study (n = 347), 
patients were randomized to one of three treatments 
(HFA-placebo, HFA-BDP 400 ug day-i or CFC- 
BDP 800 pg day-i), while the other (n = 233) com- 
prised two treatment groups (HFA-BDP 800 ug day-l 
and CFC-BDP 1500 ug day-t). At the end of the run- 
in period, plasma cortisol was determined in the 
morning (6.30-9.30 a.m. and 8-10 a.m. respectively). 
Subsequent measures, at the end of the oral steroid 
course and at the end of the 12 week study medication, 
were made within 30 min of the initial determination. 
Figure 3 shows the percentage of patients in each 
treatment group with plasma cortisol below the lower 
limit of the normal reference range after 12 weeks of 
treatment. 
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FIG. 3. Percentage of patients with morning plasma 
cortisol below the normal range after 12 weeks treat- 
ment with HFA-BDP 400 or 800 pg day-t, CFC-BDP 
800 or 1500 ug day-i, or HFA-placebo, compared 
with 7-13 days treatment with oral steroids: n , below 
reference range after oral steroids; 
range; 0, above or within reference range. 
Of those patients receiving the highest dose of BDP 
(CFC-BDP 1500 ug day-l), 14 (14.6%) were below the 
lower limit of the normal range, compared with no 
more than four patients (4.4%) in any other treatment 
group. After oral steroid treatment, plasma cortisol 
levels were below the lower limit of normal in 42% of 
patients (Fig. 3), confirming the superior safety of 
inhaled corticosteroids over oral dosing. It should be 
noted that the cortisol assay employed had a cross- 
reactivity of about 25% with prednisolone. Predni- 
solone still present in the plasma after the oral steroid 
course may therefore have produced elevated readings 
in the cortisol assay, which could have masked low 
cortisol levels. It is therefore possible that the true per- 
centage of patients with low plasma cortisol levels 
after the oral steroid course may have been even higher 
than shown in Fig. 3. 
ADVERSE EVENTS 
A total of 1429 patients have been enrolled in five 
large-scale phase III clinical trials. The overall inci- 
dence of adverse events, considered probably or possi- 
bly related to treatment, was lower in patients treated 
with HFA-BDP (11%) than in patients treated with 
CFC-BDP (16%; P=O.O12) (Table 1). Most adverse 
events were mild to moderate in intensity, with severe 
adverse events reported by 3.8% of patients in the 
HFA-BDP group, 6.8% in the CFC-BDP group and 
8.7% in the HFA-placebo group. The severe adverse 
events in the HFA-placebo group were mainly respira- 
tory system disorders (5.5% compared with 1.7% in the 
HFA-BDP group and 1.3% in the CFC-BDP group), 
confirming the need for active steroid therapy. 
The incidence of inhalation-route adverse events, 
whether related to corticosteroid presence or to pro- 
pellant and excipients (e.g. dysphonia, cough, asthma 
symptoms) was lower with HFA-BDP (8%) than with 
CFC-BDP (12%; P=O.O42) (Table 1). 
The incidence of respiratory system disorders 
and, in particular, asthma-related adverse events was 
similar in patients taking HFA-BDP and patients tak- 
ing CFC-BDP (Table 1). Not surprisingly, patients 
receiving HFA-placebo had a higher incidence of 
increased asthma symptoms (4%) than patients receiv- 
ing either active treatment (~1% for both BDP 
groups). 
Throat swabs were taken from all patients who had 
signs and symptoms indicating the possible presence 
of Cundida infection. Oral candidiasis was diagnosed 
in one patient in the CFC-BDP group. 
A review of adverse events relating to taste, includ- 
ing nausea, revealed that HFA-BDP does have a 
different taste to CFC-BDP, but that this taste is 
acceptable to most patients (17). 
SAFES OF HFA-BDP 37 
TABLE 1. Incidence of adverse events considered possibly or probably related to treatment in patients 
receiving HFA-BDP, CFC-BDP or HFA-placebo in large clinical trials [values are number of 
patients (%)] 
HFA-BDP CFC-BDP HFA-placebo Overall P value 
(n = 740) (n = 400) (n = 289) P value* HFA vs. CFC 
Patient with at least 
one adverse event 
All inhalation-route 
disorders 
Cough 
Dysphonia 
Increased 
asthma 
symptoms 
Site sensation 
Taste sensation 
All respiratory system 
disorders 
Bronchitis 
Coughing 
Increased 
asthma 
symptoms 
Laryngitis 
Pharyngitis 
Upper 
respiratory tract 
infection 
82 (11%) 
59 (8%) 
5 (<I%) 
22 (3%) 
1 (cl%) 
27 (4%) 
13 (2%) 
17 (2%) 
1 (<I%) 
1 (<I%) 
4 (Cl%) 
0 
11 (1%) 
0 
65 (16%) 
47 (12%) 
6 (2%) 
11 (3%) 
5 (1%) 
23 (6%) 
8 (2%) 
7 (2%) 
0 
0 
3 (<I%) 
1 (cl%) 
2 (Cl%) 
1 (Cl%) 
28 (10%) 0.012 0.012 
13 (4%) 0.003 0.042 
3 (1%) 
4 (1%) 
1 (cl%) 0.026 0.022 
5 (2%) 
2 (cl%) 
13 (4%) 
1 (cl%) 
1 (cl%) 
11 (4%) 
0 
1 (cl%) 
0 
The percentage of patients who withdrew from the 
studies was similar in both active treatment groups 
(8% for HFA-BDP and 10% for CFC-BDP) and 
lower than the percentage in the placebo group (21%). 
More patients in the placebo group withdrew because 
of inadequate response and worsening asthma, as 
might be expected from the lack of active prophylactic 
steroid treatment. 
Discussion 
The investigations reported here evaluated the safety 
of HFA-BDP for a range of parameters and in a 
variety of study designs. For all the parameters 
studied, HFA-BDP was shown to be at least as well 
tolerated as CFC-BDP on a ng for ng basis. 
The study on acute topical safety in asthmatic 
patients found that HFA-BDP was no more likely 
to provoke cough or a fall in FEV, after inhalation 
than CFC-BDP, CFC-placebo or HFA-placebo. This 
is consistent with the excellent tolerability already 
demonstrated for HFA in animal and healthy volun- 
teer studies (9-11) and in a clinical programme for 
HFA-salbutamol (13). It is also consistent with the 
adverse event data from the clinical trials presented 
here, showing that HFA-BDP appeared to be associ- 
ated with a lower incidence of adverse events than 
CFC-BDP. This appears to confirm the expectation 
that the HFA-BDP reformulation would generate no 
new safety issues. 
As described elsewhere (18) the HFA-BDP for- 
mulation produces an extrafine spray of droplets 
designed to improve delivery to the airways. Lung 
deposition studies (14) have confirmed that a higher 
dose of drug is delivered to the lungs and a lower pro- 
portion to the throat. As certain local side-effects 
commonly associated with the use of inhaled corticos- 
teroids (e.g. dysphonia, candidiasis) are believed to be 
related to the presence of corticosteroid in the throat, 
HFA-BDP might be expected to exhibit a low inci- 
dence of these effects. The observation of a lower 
frequency of inhalation-route adverse events in the 
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clinical trials with HFA-BDP supports this possibility. 
Of particular importance is the fact that no patient 
treated with HFA-BDP displayed symptoms of 
candidiasis. This occurred even though spacers were 
not employed in the trials and patients were not 
instructed to rinse the mouth and throat routinely 
after dosing. 
An increase in delivery of inhaled corticosteroids 
to the lung may lead to greater systemic availability 
of active glucocorticoids, as absorption via the lung 
reaches the systemic circulation directly, whereas 
absorption through the gut is subject to first-pass 
metabolism in the liver. The size of this effect differs 
with the absorption characteristics of each cortico- 
steroid. For example, as fluticasone has little or no 
oral bioavailability (19) any improvement in delivery 
to the airways may cause a significant increase in sys- 
temic drug levels. This possibility was evaluated for 
HFA-BDP by investigating its effects on adrenal 
function, a marker of systemic glucocorticoid activity 
(5). Using UFC measurement (15), the excretion of 
UFC in patients treated with doses of HFA-BDP 
ranging from 200 to 800 pg day-1 was not significantly 
different from that observed in the same study with 
CFC-BDP 800 ug day-i. The degree of suppression of 
UFC observed in this study after administration of 
CFC-BDP was greater than that reported in other 
published studies (15). This is probably because the 
patients in the study were resident in the clinic 
throughout the treatment period, thus ensuring per- 
fect compliance and good inhaler technique. Com- 
pliance with asthma medication is notoriously low 
(20-21), and many patients have poor inhaler tech- 
nique (22-25). Thus, the patients in the present study 
almost certainly had a higher exposure to BDP than 
may be expected in routine practice. The observation 
of greater suppression of 24 h UFC excretion than 
may be expected following CFC-BDP treatment is 
consistent with this. 
The same clinical pharmacology study also assessed 
the response to cosyntropin stimulation, an alternative 
measure of HPA axis function, and found that this 
was also normal in all but one subject. The single 
exception had low baseline and low post-treatment 
cortisol levels, which caused her to be classified as 
abnormal according to the study criteria. However, 
despite low absolute plasma cortisol, she displayed a 
normal incremental increase after cosyntropin stimu- 
lation, indicating that she retained intact adrenal 
responsiveness to exogenous corticotropin analogue 
administration. The clinical significance of this finding 
is uncertain. 
Morning plasma cortisol concentration, a simpler 
but less sensitive measure of adrenal function, was 
assessed in two large phase III clinical studies. The 
number of patients with plasma cortisol concentra- 
tions below the lower limit of normal did not differ 
between the groups treated with HFA-placebo, HFA- 
BDP 400 or 800 lrg day-i, or CFC-BDP 800 ug day-i, 
although there was a higher proportion in the group 
receiving CFC-BDP 1500 ug day-i. This observation 
is in agreement with published data. Adrenal suppres- 
sion has been regarded as of negligible clinical impor- 
tance in the routine management of most asthmatic 
patients on inhaled corticosteroid therapy (26) and, in 
adults, suppression of adrenal function is generally 
observed only at doses of CFC-BDP in excess of 
1000 ug day-i (27, 28). 
Thus, all three measures of HPA axis function 
found that HFA-BDP 800 ug day-1 caused no more 
adrenal suppression than CFC-BDP 800 ug day-i. 
The agreement between three different measures in 
studies of different design gives a high degree of con- 
fidence in this finding, indicating that the increased 
lung delivery of HFA-BDP is not associated with any 
greater incidence of HPA axis suppression at standard 
doses. 
With the impending phase-out of all CFC-contain- 
ing inhalers it is reassuring that the overall data sup- 
port the safe switching of CFC-BDP patients to 
HFA-BDP. The adverse event profile of CFC-BDP is 
well characterized, and the low incidence of adverse 
events for HFA-BDP compares favourably with 
CFC-BDP. These safety findings give confidence that 
the reformulation of BDP in the HFA propellant 
system has had no deleterious consequences. 
Importantly, other studies have found that the 
HFA-BDP extrafine aerosol, with its ability to deliver 
a greater proportion of administered drug to the 
lung, is associated with greater anti-asthmatic effec- 
tiveness (29, 30). Equivalent efficacy has been demon- 
strated using a dose of HFA-BDP approximately 
half that of CFC-BDP (800 ug day-i compared with 
1500 ug day-i) (30). 
With a lower dose providing equivalent efficacy, 
and equivalent safety at the same dose, the overall 
therapeutic ratio of the HFA-BDP formulation 
would appear to be substantially more favourable than 
that of the conventional CFC-BDP formulation. 
HFA-BDP appears to represent an advance in the 
treatment of asthma. 
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